tbuckley/cabot-search huggingface dataset:
Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.
Authors: R. L. Ladenstein, U. Poetschger, R. Luksch, P. Brock, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W. Balwierz, E. Ruud, P. Kogner, H. Schroeder, A. Forjaz De Lacerda, M. Beck Popovic, P. Bician, M. Garami, T. Trahair, A. D. Pearson, D. Valteau Couanet
Journal: Journal of Clinical Oncology (2011)

2 Background: The HR-NBL1 trial of the European SIOP Neuroblastoma Group randomised 2 MAT regimens with the primary aim to demonstrate superiority based on event free survival (EFS). Methods: At randomisation closure, 1,577 high-risk neuroblastoma patients (944 males) had been included since 2002; with INSS stage 4 disease (1,369 pts) &gt; 1 year, infants (65 pts) and stage II and III (143 pts) of any age with MYCN amplification. Response eligibility criteria prior to randomisation after Rapid COJEC Induction (J Clin Oncol, 2010) ± 2 courses of TVD (Cancer, 2003) included complete bone marrow remission and ≤ 3, but improved, mIBG positive spots. The MAT regimens were BuMel (oral busulfan till 2006, 4x150mg/m 2 in 4 equal doses, or after 2006 intravenous use according to body weight and melphalan 140mg/m 2 /day) and CEM (carboplatin ctn. infusion [4xAUC 4.1mg/ml.min/day], etoposide ctn. infusion [4x338mg/m 2 day or 4x200mg/m 2 /day*], melphalan [3x70mg/m 2 /day or 3x60mg/m 2 /day*. *reduced if GFR&lt;100ml/min/1.73m 2 ]). A minimum of 3x10E6 CD34/kgBW PBSC were requested. VOD prophylaxis included ursadiol, but not prophylactic defibrotide. Local control included surgery and radiotherapy of 21 Gy. A total of 598 patients were randomised (296 BuMel, 302 CEM). The median age at randomisation was 3 years (1-17.2) with a median follow up of 3 years. Results: At the last analysis, the Peto rule of p&lt;0.001 was met. A significant difference in EFS in favour of BuMel (3-years EFS 49% vs 33%) was observed as well as for overall survival (3-years OS 60% vs 48%, p=0.004). This difference was mainly related to the relapse and progression incidence, which was significantly (p&lt;0.001) lower with BuMel (48% vs 60%). The severe toxicity rate up to day 100 (ICU and toxic deaths) was below 10%, but was significantly higher for CEM (p=0.014). The acute toxic death rate was 3% for BuMel and 5% for CEM (NS). The acute MAT toxicity profile favours the BuMel regimen in spite of a total VOD incidence of 18% (grade 3:5%). Based on these results and following advice from the DMC, the randomisation was closed early. Conclusions: BuMel was demonstrated to be superior to CEM and hence is recommended as standard treatment.
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Authors: Richard G. Gray, Daniel Rea, Kelly Handley, Sarah Jane Bowden, Philip Perry, Helena Margaret Earl, Christopher John Poole, Tom Bates, Shan Chetiyawardana, John A. Dewar, Indrajit Nalinika Fernando, Robert Grieve, Jonathan Nicoll, Zenor Rayter, Anne Robinson, Asad Salman, John Yarnold, Sarah Bathers, Andrea Marshall, Martin Lee
Journal: Journal of Clinical Oncology (2013)

5 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
PATH-32. MOLECULAR HETEROGENEITY AMONG PEDIATRIC POSTERIOR FOSSA EPENDYMOMA
Authors: Kristian W Pajtler, Ji Wen, Martin Sill, Tong Lin, Jens Hübner, Vijay Ramaswamy, David Jones, Hendrik Witt, Lukas Chavez, Ruth Tatevossian, Richard Grundy, Thomas Merchant, Arzu Onar-Thomas, Michael Taylor, Stefan M Pfister, Andrey Korshunov, Marcel Kool, David W Ellison
Journal: Neuro-Oncology (2017)

Previously, we have identified nine distinct molecular groups of ependymoma across all age groups, three in each major anatomical compartment of the CNS: spinal, posterior fossa, and supratentorial. These nine molecular groups are genetically, epigenetically, transcriptionally, demographically, and clinically distinct. Pediatric intracranial ependymomas are either affiliated with the RELA and YAP1 supratentorial groups or with the posterior fossa PFA group. RELA and YAP1 ependymomas harbor recurrent and distinct fusion genes that drive the disease, but PFA ependymomas lack significant recurrent mutations, and the specific oncogenic events underlying these tumors remain undefined. Observing distinct outcomes among children with PFA ependymomas, we tested the hypothesis that further molecular diversity with clinical utility, including possible novel genetic alterations, may exist among these tumors. Genome-wide DNA methylation profiles of 675 pediatric PFA ependymomas were analyzed by unsupervised consensus hierarchical clustering and t-distributed stochastic neighbor embedding (tsne), which identified not only three major distinct molecular subgroups of PFA ependymoma: PFA-1, PFA-2, and PFA-3, but additional small subgroups that segregate within PFA-1 and PFA-2. Subgroups were characterized by distinct clinical and genetic characteristics; most PFA-3 tumors harbored 1q gain and occurred in children significantly older than those with PFA-1 and PFA-2 tumors. Some of the small subgroups demonstrated distinctive copy number alterations or gene mutations, e.g. H3 K27M. Outcome data revealed considerable heterogeneity among the different subgroups, overall survival at 5 years was >90% for one subgroup, but <20% for two others. We conclude that further molecular refinement of pediatric PFA ependymomas has clinical utility and the potential for enhanced risk assessment or therapeutic stratification. In addition, identification of PFA subgroups and further molecular heterogeneity within these subgroups may help to identify the drivers of PFA ependymomas.
Just Words
Authors: Alexander Gode
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RNA TRANSPORT
Authors: Sara Nakielny, Utz Fischer, W. Matthew Michael, Gideon Dreyfuss
Journal: Annual Review of Neuroscience (1997)

RNA molecules synthesized in the nucleus are transported to their sites of function throughout the eukaryotic cell by specific transport pathways. This review focuses on transport of messenger RNA, small nuclear RNA, ribosomal RNA, and transfer RNA between the nucleus and the cytoplasm. The general molecular mechanisms involved in nucleocytoplasmic transport of RNA are only beginning to be understood. However, during the past few years, substantial progress has been made. A major theme that emerges from recent studies of RNA transport is that specific signals mediate the transport of each class of RNA, and these signals are provided largely by the specific proteins with which each RNA is associated.
Exercise Physiology and Rehabilitation in <i>Circulation</i> and the <i>Circulation</i> Subspecialty Journals
Journal: Circulation (2012)

The following articles are being highlighted as part of Circulation's Topic Review series. This series will summarize the most important manuscripts, as selected by the editors, published in Circulation and the Circulation subspecialty journals. The studies included in this article represent the articles related to exercise physiology and rehabilitation that were published in Circulation and its subspecialty journals in 2010 and 2011.
Development of a financial navigation program to ease the burden of financial toxicity.
Authors: Melissa Monak, Kimberly Bell, Antoinette Whitt
Journal: Journal of Clinical Oncology (2019)

6565 Background: Due to the rising cost of cancer care, even well-insured patients are at risk for financial toxicity. Cancer treatment costs can be challenging for patients and families because of increasing deductibles, increasing premiums and frequent co-payments. At Cleveland Clinic Cancer Centers, our goal is to identify patients at risk for financial distress and help ease the financial stress and hardship associated with cancer care. Methods: In 2015 we initiated huddles for all new patients to ensure seven day access for our patients as well as out of network authorizations. During this work we identified the need for a position to help manage the costs of care for our patients. The Financial Navigator (FN) role was created in 2016 to complete benefits investigations to determine covered services and minimize the patient’s out of pocket expenses. We are participants in the Oncology Care Model and are expected to provide and document the estimated out-of-pocket costs in the patient’s medical record. Navigators conduct telephone outreach calls with treatment patients to educate them on their benefits. The FN also assists with applications on copay assistance and free drug options. Finally, the FN will connect patients with resources for premium assistance and household expenses when copay assistance isn’t an option. The FN team has grown to 7 FTE’s since 2016. Results: Since 2016 the dollar amount approved through copay assistance applications has increased by 70%, the free drug value received increased by 55%, and end of year 2018 data shows that we more than doubled what was collected towards patient out of pocket costs from copay assistance programs compared to 2017. We have also been able to comply with the out of pocket expense metric for OCM, not only for our Medicare patients, but for all of our treatment patients and compliance has risen from 44% in December 2017 to 98% in April 2018 and we continued to obtain a goal of 96% or higher throughout 2018. Conclusions: In conclusion our Navigators have built relationships with Social Workers, Care Coordinators, and community services that are available to patients. This added benefit helps patients with non-medical financial stressors. The team can connect patients to organizations that can assist with household utilities, childcare concerns, food concerns, and mortgages. Utilization of the FN role has helped the healthcare team and patients to identify ways to mitigate the costs of care and distress related to financial concerns.
Changing the needle when inoculating blood cultures. A no-benefit and high-risk procedure
Authors: M. K. Leisure
Journal: JAMA (1990)

Although the Centers for Disease Control recommends that needles should never be recapped, many phlebotomists routinely recap and change needles before blood culture inoculation. This study compared the extrinsic contamination rate in blood cultures when the needle was and was not changed. One hundred eight medical students obtained 182 blood specimens from each other by means of standard methods. Each specimen was inoculated into two culture bottles. The first bottle was inoculated with the needle used for phlebotomy, and the second was inoculated after needle change. Four (2.2%) of 182 bottles were contaminated when the needle was not changed, compared with one (0.6%) when the needle was changed. This small difference was not statistically significant, and the likelihood of having failed to detect a 5% difference in contamination rate was small. The risk of needle-stick injury incurred by changing the needle before inoculation of blood culture bottles seems to be unjustified. (<i>JAMA</i>. 1990;264:2111-2112)
Familial Aggregation of Lung Cancer in Humans
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Auriculotherapy
Authors: Paul F. M. Nogier
Journal: JAMA (1984)

<h3>To the Editor.—</h3> At the request of my American colleagues, I offer my opinion on the article by Melzack and Katz<sup>1</sup>published in the Feb 24 issue ofThe Journal. I have serious reservations about the technique used in this study as well as the proposed conclusions. The purpose of this study was to evaluate auriculotherapy in patients suffering from chronic pain. It has not been shown in the work by Melzack and Katz how long the patients had been suffering from pain. One may suppose that these chronic conditions had existed for many years or at least several months. We know that chronic pain, although perceived in specific sites, also affects more central zones of the nervous system, such as the periaqueductal gray matter, the lateroventroposterior nucleus of the thalamus, and the cortex. These were mentioned only as some of the more important parts. Thus, the points of
Childhood Cancer
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Medical Biometry and Statistics . By Raymond Pearl, Ph.D., Sc.D., LL.D., Professor of Biology in the School of Hygiene and Public Health, and in the Medical School, Johns Hopkins University, Baltimore, Md. 459 pages. Second Edition, Revised and Enlarged. Philadelphia and London: W. B. Saunders Company, 1930. Cloth, $5.50.
Journal: New England Journal of Medicine (1931)
Vasectomy and prostate cancer. Chance, bias, or a causal relationship?
Authors: S. S. Howards
Journal: JAMA (1993)

This issue ofThe Journalincludes two reports of cohort studies by Giovannucci et al that find an association between vasectomy and subsequent risk of prostate cancer.<sup>1,2</sup>Both vasectomy and prostate cancer are common and any causal relationship between the two would be important both for individual and public health. Although the studies by Giovannucci et al are of high quality, whether the relationship they report on is causal remains unclear. The age-adjusted relative risks for prostate cancer among men with vasectomy in the Nurses' Health Study and the Health Professionals Follow-up Study were 1.56 (95% confidence interval, 1.03 to 2.37) and 1.66 (95% confidence interval, 1.25 to 2.21), respectively. When risk estimates of this magnitude are derived from observational studies, they are considered to be weak associations that may be due to chance, bias, or a causal relationship.<sup>3</sup>It is our See also pp 873 and 878.
Simvastatin as a Treatment for Pulmonary Hypertension Trial
Authors: M. R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, C. J. Rhodes, H. A. Ghofrani, L. Howard, P. Nihoyannopoulos, R. H. Mohiaddin, J. S. R. Gibbs
Journal: American Journal of Respiratory and Critical Care Medicine (2010)
Acute renal failure during treatment with ticrynafen
Authors: H. Sawa
Journal: JAMA (1980)

TICRYNAFEN is a new antihypertensive, uricosuric diuretic.<sup>1,2</sup>Substantial uricosuria may complicate the initial response to the drug. Because renal tubular blockade by the precipitation of uric acid is possible, discontinuation of current diuretic therapy for three days and liberalization of fluid intake before the initiation of ticrynafen therapy has been suggested (Philip J. Tannenbaum, MD, Smith Kline &amp; French Laboratories, written communication, Sept 17, 1979). We describe here a case of acute renal failure during treatment with ticrynafen used as the sole antihypertensive agent. <h3>Report of a Case</h3> A 52-year-old physician, a known hypertensive for the last six years, was controlled with chlorthalidone, 100 mg daily. In May 1979, his blood pressure was 132/82 mm Hg. The BUN level was 14 mg/dL, with serum creatinine level of 0.9 mg/dL. Results of urinalysis were normal. Complete blood cell count was normal, with a hematocrit value of 41.4%. Because of an
Bacteriuria during indwelling catheter drainage. Effect of constant bladder rinse
Authors: G. F. Thornton
Journal: JAMA (1966)

Thirty-three patients requiring prolonged drainage of the urinary bladder in 35 separate instances were treated with a constant bladder irrigation of a dilute solution of neomycin sulfate and polymyxin B sulfate. This system was highly effective in preventing the acquisition of bacteriuria caused by gram-negative rod forms in patients with initially sterile urine if the catheter remained in place for ten days or less, but it was considerably less effective in preventing acquired bacteriuria when catheter drainage was required for periods in excess of ten days. The bladder rinse was not effective in eradicating preexisting bacteriuria. Although complications of therapy were minimal, prolonged irrigation with neomycin-polymyxin B solution seemed to predispose to acquired bacteriuria or superinfection with<i>Proteus</i>species and enterococci which were usually resistant to at least one of these antibiotics.
Practitioner's Handbook of Materia Medica and Therapeutics. Based on Physiologic Actions and the Indications in Small Doses, to Which Is Added Some Pharmaceutical Data.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.
Authors: Andrew J. Armstrong, Ping Lin, Celestia S. Higano, Cora N. Sternberg, Guru Sonpavde, Bertrand F. Tombal, Arnoud J. Templeton, Karim Fizazi, De Phung, Elaine K Wong, Andrew Krivoshik, Tomasz M. Beer
Journal: Journal of Clinical Oncology (2017)

5022 Background: Prognostic models require updating to reflect contemporary medical practice. In a post hoc analysis of the phase 3 PREVAIL trial (enzalutamide vs placebo), we identified prognostic factors for overall survival (OS) in chemotherapy-naive men with mCRPC. Methods: Patients were randomly divided 2:1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined candidate prognostic factors (including treatment) were analyzed in a multivariable Cox model with stepwise procedures and in a penalized Cox proportional hazards model using the adaptive least absolute shrinkage and selection operator (LASSO) penalty (data cutoff June 1, 2014). A multivariable model predicting OS was developed using the training set; the predictive accuracy was assessed in the testing set using time-dependent area under the curve (tAUC). The testing set was stratified based on risk score tertiles (low, intermediate, high), and OS was analyzed using Kaplan-Meier methodology. Results: Demographics, disease characteristics, and OS were balanced between the training and testing sets; median OS was 32.7 months for both datasets. There were no enzalutamide treatment-prognostic factor interactions (predictors). The final multivariable model included 11 prognostic factors: prostate-specific antigen, treatment, hemoglobin, neutrophil-lymphocyte ratio, liver metastases, time from diagnosis to randomization, lactate dehydrogenase, ≥ 10 bone metastases, pain, albumin, and alkaline phosphatase. The tAUC was 0.74 in the testing set. Median (95% confidence interval [CI]) OS for the low-, intermediate-, and high-risk groups (testing set) were not yet reached (NYR) (NYR–NYR), 34.2 months (31.5–NYR), and 21.1 months (17.5–25.0). The hazard ratios (95% CI) for OS in the low- and intermediate-risk groups vs the high-risk group were 0.20 (0.14–0.29) and 0.40 (0.30–0.53), respectively. Conclusions: Our validated prognostic model incorporates factors routinely collected in chemotherapy-naive men with mCRPC treated with enzalutamide and identifies subsets of men with widely differing survival times. Clinical trial information: NCT01212991.